Sarno Manoel, Cavalcante Marcelo Borges, Niag Marla, Pimentel Kleber, Luz Ivana, Figueiredo Bianca, Michelon Tatiana, Neumann Jorge, Lima Simone, Machado Isabela Nelly, Araujo Júnior Edward, Barini Ricardo
Department of Obstetrics and Gynecology, Federal University of Bahia (UFBA), Salvador, BA, Brazil.
Department of Obstetrics and Gynecology, Fortaleza University (UNIFOR), Fortaleza, CE, Brazil.
Eur J Obstet Gynecol Reprod Biol X. 2019 May 7;3:100036. doi: 10.1016/j.eurox.2019.100036. eCollection 2019 Jul.
This study aims to elucidate which types of recurrent miscarriage (RM) patients experienced a livebirth after paternal lymphocyte immunotherapy (LIT) and to evaluate the perinatal outcome.
Retrospective analysis of a multicenter, observational study which enrolled 1096 couples with a history of two or more spontaneous miscarriages without any intercalated delivery. We conducted an intention-to-treat analysis of couples with RM treated with or without LIT regarding to gestational and perinatal outcomes. We compared groups by using the Student's -test or Kruskal-Wallis test, Fisher's exac-test and test when appropriate.
The success of gestation was significantly higher in the LIT group (60.1% vs. 33.1%; < 0.001). A sub-analysis of four different immune disorder groups revealed a significantly higher success in the LIT group in all immune categories, except in patients who had autoantibodies positive. We observed no significant differences in perinatal outcomes such as gestational age at birth, preterm and extreme preterm birth, and birth weight in successful pregnancy in both groups. The success rate was significantly higher when LIT was administrated before and during pregnancy and only during pregnancy compared to only before pregnancy ( < 0.01).
Careful laboratory test phenotyping of RM patients may identify subgroups most likely to benefit and exclude those with little likelihood of benefit, and LIT during a pregnancy may significantly improve success rates.
本研究旨在阐明哪些类型的复发性流产(RM)患者在接受父淋巴细胞免疫疗法(LIT)后成功分娩,并评估围产期结局。
对一项多中心观察性研究进行回顾性分析,该研究纳入了1096对有两次或更多次自然流产史且无中间分娩的夫妇。我们对接受或未接受LIT治疗的RM夫妇的妊娠和围产期结局进行了意向性分析。我们在适当的时候使用学生t检验或Kruskal-Wallis检验、Fisher精确检验和卡方检验对各组进行比较。
LIT组的妊娠成功率显著更高(60.1%对33.1%;P<0.001)。对四个不同免疫紊乱组的亚分析显示,除自身抗体阳性的患者外,LIT组在所有免疫类别中的成功率均显著更高。我们观察到两组成功妊娠的围产期结局,如出生时的孕周、早产和极早产以及出生体重,均无显著差异。与仅在妊娠前相比,在妊娠前和妊娠期间以及仅在妊娠期间进行LIT时,成功率显著更高(P<0.01)。
对RM患者进行仔细的实验室测试表型分析可能会识别出最有可能受益的亚组,并排除受益可能性较小的亚组,并且在妊娠期间进行LIT可能会显著提高成功率。